Stoke Therapeutics, Inc. has grown revenue 146% a year over three years and 146% a year over five. Revenue growth, 3-year annual rate: +146% (Biotechnology median +17%). Revenue growth, 5-year rate: +146%, growth has slowed since the five-year average. Years of annual history on file: 8, FY2018 to FY2025, as filed.

STOKStoke Therapeutics, Inc.

Healthcare

$24.71+7.9% 1Y

$24.71

$22.3752 weeks$38.35

Is it growing?

Watch

Growth is fading: revenue shrinking (−86% year on year) and operating margin narrowing (−1386.5 points).

2 to watch, 1 without data

Revenue trend−86% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Margin direction−1386.5 points operating

Trailing-twelve-month operating margin, -1586.7% now against -200.2% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is STOK growing?

Stoke Therapeutics, Inc. has grown revenue 146% a year over three years and 146% a year over five.

+146%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +146%
Revenue growth, 5-year rate · +146% over three · growth has slowed since the five-year average
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed

Details›